🇺🇸 Sitagliptin (Januvia) in United States

14 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Condition Aggravated — 2 reports (14.29%)
  2. Cough — 2 reports (14.29%)
  3. Dyspnoea — 2 reports (14.29%)
  4. Fatigue — 2 reports (14.29%)
  5. Agitation — 1 report (7.14%)
  6. Amnesia — 1 report (7.14%)
  7. Ankle Fracture — 1 report (7.14%)
  8. Anxiety — 1 report (7.14%)
  9. Apathy — 1 report (7.14%)
  10. Apnoea — 1 report (7.14%)

Source database →

Other Diabetes approved in United States

Frequently asked questions

Is Sitagliptin (Januvia) approved in United States?

Sitagliptin (Januvia) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Sitagliptin (Januvia) in United States?

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is the originator. The local marketing authorisation holder may differ — check the official source linked above.